| Abstrakt: |
Introduction: cholemic nephropathy is renal injury induced by bile duct ligation (cholestasis). Sitagliptin is an oral dipeptidyl peptidase-4 inhibitor that inhibits the glucose-dependent insulinotropic polypeptide hormone and is effective in controlling blood glucose in diabetic patients. It is suggested that sitagliptin has antioxidant and antiinflammatory effects. Considering the role of oxidative stress and inflammation caused by cholestasis, the effects of sitagliptin on kidney damage were investigated in an experimental model of cholemic nephropathy. Methods and Materials: In this study, 28 male Wistar rats (180 to 220 gr) were used, which were divided into 6 groups (n=7), including sham, sham+Sit 50 mg/kg, bile duct ligation (BDL) and BDL groups received different doses (10, 50 and 100 mg/kg) of sitagliptin. The drug was administered by gavage for two weeks and after the end of two weeks, the rats were sacrificed and their blood and kidney tissue were collected for further measurements. Results: Cholestasis increased serum levels of aspartate transferase and alkaline transferase, which is liver injury index, administration of 10mg/Kg sitagliptin improves this index. Serum urea and creatinine increased in consequence of BDL, administration of low dose of sitagliptin reduced these two factors to sham group levels. Malondialdehyde (MDA), TNF-α, and sestrin-2 levels increased in kidney tissue of BDL group, while sitagliptin treatment reduced inflammation and oxidative stress due to increase superoxide dismutase enzyme activity and total anti-oxidant capacity. Conclusion: In addition to liver injury, cholestasis causes renal injury through induction of inflammation and activation of oxidative stress pathway. Sitagliptin administration especially in lower dose reduced renal injury through augmentation of anti-oxidant defense and inflammation. [ABSTRACT FROM AUTHOR] |
